DARZALEX FASPRO
Aug 05, 2024
DARZALEX FASPRO Regimen Approval: Johnson & Johnson Howling Success in Multiple Myeloma
Despite significant progress in multiple myeloma treatment with a range of biological drugs and their combinations—such as IMiDs (BMS REVLIMID, POMALYST/IMNOVID), anti-CD38 monoclonal antibody drugs (DARZALEX, SARCLISA), the anti-SLAM7 monoclonal antibody (AbbVie and BMS multiple myeloma drug EMPLICITI), and new pr...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
